FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Sunday

 

SATIVEX: "GW Pharmaceuticals: High As A Kite And Too Close To The Sun"


"GW's lead product, Sativex is now approved or recommended for approval in 24 minor countries, such as Norway, Israel, and Austria. It is indicated as a treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS) that have not responded adequately to other anti-spasticity medication.

  
GW has now entered into five separate licensing agreements for Sativex with Bayer HealthCare in the UK and Canada; Almirall in Europe and Mexico; Otsuka Pharmaceutical Co. Ltd. in the United States; Novartis in the Middle East, Africa, and Asia; and Neopharm in Israel. Over the ~10-year history of Sativex production, GW has generally been operating at a cash flow loss due to limited sales of the product and expensive ongoing operating costs for the corporate entity.

Founded in 1998 to monetize a product portfolio of cannabinoid prescription medicines to meet patient needs under medical supervision, GW Pharmaceuticals has purportedly assembled a large in-house team with extensive experience in developing cannabinoids, medicines containing controlled substances, as well as plant-based prescription pharmaceutical products.

Marijuana Hype Overplayed: GW Pharmaceuticals will derive no benefit from the

nascent retail marijuana market opportunity in Colorado, Washington, and other legalizing states.
 

Corrupted Research: The purported "research literature" regarding marijuana plant-derived cannabidiol (CBD) use in pediatric treatment-resistant epilepsy seems especially dubious because GW Pharmaceuticals has corrupted the objectivity of the authors by being their financial backers; it has failed to disclose this critical fact in SEC filings or investor materials.
 

Limited Intellectual Property & Pricing Power: Because GW Pharmaceuticals' main products are natural plant-derived extracts, they cannot be patented and there are basically no barriers to other firms extracting and selling the same biologicals. For example, just because orange juice is demonstrated to provide a health benefit doesn't mean that a company can earn outsized returns by selling concentrated Vitamin C.


Marijuana Hype Overplayed

GW Pharmaceuticals' sole business model is the monetization of a product portfolio of cannabinoid prescription medicines to meet patient needs under direct medical supervision. The Company will derive no benefit from the nascent retail marijuana market opportunity in Colorado, Washington, and other legalizing states. As an analogy, after the repeal of Prohibition in 1933, the businesses that prospered were the ex-bootlegger brewers such as Anheuser-Busch, not a pharmaceutical firm that was attempting to study the medical benefits of a daily glass of wine in the prevention of cardiac disease."


READ THE FULL STORY

Labels:



Go to Newer News Go to Older News